Hyperbaric oxygen therapy-a new hope for Alzheimer’s patients: a case report and literature review
Elizabeta B. Mukaetova-Ladinska , Joanna Steptoe , Matthew Critchfield , Ha-Jun Yoon , Mishaal Sharif , Qadeer Arshad
Exploration of Neuroprotective Therapy ›› 2023, Vol. 3 ›› Issue (6) : 457 -469.
The currently available pharmacological anti-dementia treatments provide only temporary and limited benefits. Not surprisingly, patients and professionals increasingly explore non-pharmacological interventions that may alleviate dementia symptoms. Among these interventions is hyperbaric oxygen therapy (HBOT). A brief review is presented on HBOT use in medicine, with its mode of action in dementia, specifically Alzheimer’s disease, as well as a case report of self-initiated HBOT in a 62-year-old man with a clinical diagnosis of probable Alzheimer’s disease. He had over 400 HBOT sessions [2–3 times weekly, with a duration of 30–50 min, in a multi-place hyperbaric chamber at 2 atmospheres absolute (ATA)] over 7 years and use of donepezil (10 mg daily) for the last 3 years when formally diagnosed by the National Health Service (NHS) Memory Service. The patient’s longitudinal neurocognitive and neuroradiological evidence over 7 years of follow-up remained stable (with no major cognitive decline and no behavioral changes) when compared to his initial presentation when diagnosed by the private health provider. His driving remains unimpaired, and he continues to be independent. This highlights the potential HBOT benefits including those on visuospatial ability and activities of daily living in people with Alzheimer’s disease. This case report argues for more extensive research into the clinical effects of HBOT in Alzheimer’s disease. Discussion of HBOT use is along with the latest advances in anti-amyloid immunotherapy for Alzheimer’s disease, as well as HBOT augmentation of current and novel dementia drug delivery via nanotechnology.
Hyperbaric oxygen therapy / Alzheimer’s disease / dementia / non-pharmacological treatment / nanomedicine
| [1] |
Ageing and health [Internet]. Geneva: World Health Organization; c2023 [cited 2023 Sep 14]. Available from: https://www.who.int/news-room/fact-sheets/detail/ageing-and-health |
| [2] |
The global health observatory [Internet]. Geneva: World Health Organization; c2023 [cited 2023 Sep 15]. Available from: https://www.who.int/data/gho |
| [3] |
|
| [4] |
|
| [5] |
Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014; 13: 57-65. |
| [6] |
|
| [7] |
Dementia [Internet]. Geneva: World Health Organization; c2023 [cited 2023 Sep 15]. Available from: https://www.who.int/news-room/fact-sheets/detail/dementia |
| [8] |
|
| [9] |
Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, |
| [10] |
National Institute for Health and Care Excellence (NICE). Dementia: assessment, management and support for people living with dementia and their carers. London: The Institute; 2018. |
| [11] |
|
| [12] |
Alternative therapies for dementia [Internet]. London: Alzheimer’s Society; c2023 [cited 2023 Sep 16]. Available from: https://www.alzheimers.org.uk/about-dementia/treatments/alternative-therapies-dementia |
| [13] |
|
| [14] |
Ortega MA, Fraile-Martinez O, García-Montero C, Callejón-Peláez E, Sáez MA, Álvarez-Mon MA, |
| [15] |
Undersea and Hyperbaric Medical Society, Hyperbaric Oxygen Committee. Hyperbaric oxygen therapy indications. 14th ed. |
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
Maroon JC. The effect of hyperbaric oxygen therapy on cognition, performance, proteomics, and telomere length-the difference between zero and one: a case report. Front Neurol. 2022; 13: 949536. |
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
Hachmo Y, Hadanny A, Abu Hamed R, Daniel-Kotovsky M, Catalogna M, Fishlev G, |
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
Hyperbaric oxygen therapy for prodromal Alzheimer’s disease with cerebrovascular disease [Internet]. Bethesda (MD): National Library of Medicine; [cited 2023 Sep 17]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05349318 |
| [45] |
|
| [46] |
|
| [47] |
Hampel H, Elhage A, Cho M, |
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
Peng H, Yao F, Zhao J, Zhang W, Chen L, Wang X, |
| [52] |
|
/
| 〈 |
|
〉 |